ALK-Abelló A/S (ALK-B.CO)
Develops allergy treatments including immunotherapy tablets, injections, and emergency adrenaline sprays.
226.20+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+19.7%
The outlook
ALK-B.CO trades at 226.2 with a strong buy consensus from analysts, whose average price target sits about 32% above the current level. The stock is positioned midway in its 52-week range but trades below both its 50- and 200-day moving averages, reflecting recent weakness despite the bullish analyst lean. The overall sentiment leans bullish, though the elevated trailing P/E of 39 warrants consideration.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range54% of the way from its 52-week low to high
Price targetAvg target +32% vs current price
Analyst price target
~12-month · 4 analysts298.75average target+32.1% vs now
Now 226.20
Low 290.00High 305.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$50.12B
52-wk high
271.40
52-wk low
172.40
50-day avg
251.83
200-day avg
228.59
Trailing P/E
39.0